MINE regimen: Difference between revisions

	WikiDoc Resources for MINE regimen
Articles
Most recent articles on MINE regimen Most cited articles on MINE regimen Review articles on MINE regimen Articles on MINE regimen in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on MINE regimen Images of MINE regimen Photos of MINE regimen Podcasts & MP3s on MINE regimen Videos on MINE regimen
Evidence Based Medicine
Cochrane Collaboration on MINE regimen Bandolier on MINE regimen TRIP on MINE regimen
Clinical Trials
Ongoing Trials on MINE regimen at Clinical Trials.gov Trial results on MINE regimen Clinical Trials on MINE regimen at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on MINE regimen NICE Guidance on MINE regimen NHS PRODIGY Guidance FDA on MINE regimen CDC on MINE regimen
Books
Books on MINE regimen
News
MINE regimen in the news Be alerted to news on MINE regimen News trends on MINE regimen
Commentary
Blogs on MINE regimen
Definitions
Definitions of MINE regimen
Patient Resources / Community
Patient resources on MINE regimen Discussion groups on MINE regimen Patient Handouts on MINE regimen Directions to Hospitals Treating MINE regimen Risk calculators and risk factors for MINE regimen
Healthcare Provider Resources
Symptoms of MINE regimen Causes & Risk Factors for MINE regimen Diagnostic studies for MINE regimen Treatment of MINE regimen
Continuing Medical Education (CME)
CME Programs on MINE regimen
International
MINE regimen en Espanol MINE regimen en Francais
Business
MINE regimen in the Marketplace Patents on MINE regimen
Experimental / Informatics
List of terms related to MINE regimen

← Older edit Newer edit →

VisualWikitext

Revision as of 20:24, 30 March 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Synonyms and keywords:Mesna-Ifosfamide-Novantrone-Etoposide Regimen; MINE Regimen

Overview

MINE regimen refers to a regimen consisting of mesna, ifosfamide, mitoxantrone and etoposide used to treat relapsed or refractory Hodgkin's lymphoma and Non-Hodgkin's lymphoma.^[1]

Regimen

MMesna

IIfosfamide

NMitoxantrone (Novantrone)

EEtoposide

Indications

Hodgkin's lymphoma and Non-Hodgkin's lymphoma^[1]

References

↑ ^1.0 ^1.1 Rehwald U, Schulz H, Reiser M, Sieber M, Staak JO, Morschhauser F; et al. (2003). "Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group". Blood. 101 (2): 420–4. doi:10.1182/blood.V101.2.420. PMID 12509381.

[pmid12509381-1] 1.0 ^1.1 Rehwald U, Schulz H, Reiser M, Sieber M, Staak JO, Morschhauser F; et al. (2003). "Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group". Blood. 101 (2): 420–4. doi:10.1182/blood.V101.2.420. PMID 12509381.

[1]

@@ Line 6: / Line 6: @@
 ==Overview==
-{{PAGENAME}} refers to a regimen consisting of [[mesna]], [[ifosfamide]], [[mitoxantrone]] and [[etoposide]] used to treat relapsed or refractory [[Hodgkin's lymphoma]] and [[Non-Hodgkin's lymphoma]].<ref name="pmid16351801">{{cite journal| author=Fan Y, Huang ZY, Luo LH, Yu HF| title=[MINE regimen for patients with relapsed or chemo-resistant invasive non-Hodgkin's lymphoma]. | journal=Ai Zheng | year= 2005 | volume= 24 | issue= 12 | pages= 1503-6 | pmid=16351801 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16351801 }} </ref><ref>{{Cite web | title = NCI Thesaurus | accessdate =  | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63440&ns=NCI_Thesaurus}}</ref>
+{{PAGENAME}} refers to a regimen consisting of [[mesna]], [[ifosfamide]], [[mitoxantrone]] and [[etoposide]] used to treat relapsed or refractory [[Hodgkin's lymphoma]] and [[Non-Hodgkin's lymphoma]].<ref name="pmid12509381">{{cite journal| author=Rehwald U, Schulz H, Reiser M, Sieber M, Staak JO, Morschhauser F et al.| title=Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. | journal=Blood | year= 2003 | volume= 101 | issue= 2 | pages= 420-4 | pmid=12509381 | doi=10.1182/blood.V101.2.420 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12509381  }} </ref>
 ==Regimen==
@@ Line 18: / Line 18: @@
 ==Indications==
-[[Hodgkin's lymphoma]] and [[Non-Hodgkin's lymphoma]]<ref name="pmid16351801">{{cite journal| author=Fan Y, Huang ZY, Luo LH, Yu HF| title=[MINE regimen for patients with relapsed or chemo-resistant invasive non-Hodgkin's lymphoma]. | journal=Ai Zheng | year= 2005 | volume= 24 | issue= 12 | pages= 1503-6 | pmid=16351801 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16351801 }} </ref><ref>{{Cite web | title = NCI Thesaurus | accessdate =  | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63440&ns=NCI_Thesaurus}}</ref>
+[[Hodgkin's lymphoma]] and [[Non-Hodgkin's lymphoma]]<ref name="pmid12509381">{{cite journal| author=Rehwald U, Schulz H, Reiser M, Sieber M, Staak JO, Morschhauser F et al.| title=Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. | journal=Blood | year= 2003 | volume= 101 | issue= 2 | pages= 420-4 | pmid=12509381 | doi=10.1182/blood.V101.2.420 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12509381  }} </ref>
 ==References==